Nanobiotix S.A.
No SEC Form 4 filings for $NBTX in the last 30 days.
Nanobiotix said it has closed its global offering, including the underwriters’ option for additional shares/ADSs. After full option exercise, it issued 2,218,467 ordinary shares (225,373 ADSs plus 33,805 additional ADSs) and 345,099 pre-funded warrants, raising about $100 million (€86.1 million) gross. Net proceeds will fund JNJ-1900 (<10%), Nanoprimer (50–60%), and general purposes (30–40%).
Nanobiotix S.A. (NASDAQ:NBTX) experienced a significant 75.8% decrease in short interest during February, with total short interest falling to 15,389 shares. Analysts generally hold a "Moderate Buy" consensus rating with an average price target of $20.00, though the stock recently traded at $38.65, well above analyst targets. Institutional investors have also been adjusting their holdings, with Royal Bank of Canada notably increasing its position.
U.S. stock futures were lower this morning, with the Dow futures falling around 0.1% on Tuesday. Shares of Semtech Corp ( NASDAQ:SMTC ) fell sharply in pre-market trading as the company reported mixed financial results for the third quarter of fiscal 2026.
